Biomarkers can Reveal Timing for Cancer Drugs to Act

A biomarker named CD109 that can visualize blood vessel activity can optimize the timing of anticancer therapies including anti-angiogenics. Tumor growth needs the formation of new blood vessels (angiogenesis). Angiogenesis inhibitors alone have failed to invoke significant response rates or prolong survival in solid tumor patients.
Email bookmark
Font : A-A+

Related Links